You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 榮昌生物-B(9995.HK)高開14.99% 與Seagen訂立許可協議以開發及商業化維迪西妥單抗
格隆匯 08-10 09:26
格隆匯8月10日丨榮昌生物-B(9995.HK)高開14.99%,報112.4港元,最新市值550億港元。榮昌生物昨日晚間發公吿稱,公司與Seagen Inc.訂立獨家全球許可協議,以開發及商業化維迪西妥單抗。根據許可協議(其中包括),Seagen獲授獨家許可,在保留為榮昌生物地區的國家以外的全球其他國家(“Seagen地區”)開發及商業化抗HER2抗體藥物偶聯物(ADC)維迪西妥單抗(RC48,商品名:愛地希®)。榮昌生物地區包括大中華區、亞洲所有其他國家(日本、新加坡除外)。根據許可協議及在其條款及條件的規限下,公司將收取首付款2億美元及最多為24億美元的里程碑付款。Seagen亦將向公司支付根據維迪西妥單抗在Seagen地區銷售的金額計算的特許權使用費。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account